<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "JATS-journalpublishing1.dtd">
<article article-type="review-article" dtd-version="1.0" xml:lang="hr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LV</journal-id>
<journal-id journal-id-type="nlm-ta">Lijec Vjesn</journal-id>
<journal-title-group>
<journal-title>Lijecnicki Vjesnik</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Lijec. Vjesn.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="ppub">0024-3477</issn>
<issn pub-type="epub">1849-2177</issn>
<publisher><publisher-name>Croatian Medical Association</publisher-name></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">LV-148-192</article-id>
<article-id pub-id-type="doi">10.26800/LV-148-5-6-7</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group>
</article-categories>
<title-group>
<article-title>Klaudini i upalne bolesti crijeva</article-title>
<trans-title-group xml:lang="en">
<trans-title>Claudins and inflammatory bowel disease</trans-title>
</trans-title-group>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes"><name><surname>Kne&#x017E;evi&#x0107;</surname><given-names>Biljana</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mustapi&#x0107;</surname><given-names>Sanda</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bani&#x0107;</surname><given-names>Marko</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Po&#x017E;gaj</surname><given-names>Lidija</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Erakovi&#x0107; Haber</surname><given-names>Vesna</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib>
<aff id="aff1"><label>1</label><institution>Zavod za gastroenterologiju, hepatologiju i klini&#x010D;ku prehranu, Klinika za unutarnje bolesti, Klini&#x010D;ka bolnica Dubrava</institution>, <addr-line>Zagreb</addr-line></aff>
<aff id="aff2"><label>2</label><institution>Medicinski fakultet Sveu&#x010D;ili&#x0161;ta u Zagrebu</institution>, <addr-line>Zagreb</addr-line></aff>
<aff id="aff3"><label>3</label><institution>Medicinski fakultet Sveu&#x010D;ili&#x0161;ta u Rijeci</institution>, <addr-line>Rijeka</addr-line></aff>
<aff id="aff4"><label>4</label><institution>Selvita d.o.o.</institution>, <addr-line>Zagreb</addr-line></aff>
</contrib-group>
<author-notes>
<corresp id="cor1">Adresa za dopisivanje: Biljana Kne&#x017E;evi&#x0107;, dr. med., Zavod za gastroenterologiju, hepatologiju i klini&#x010D;ku prehranu, Klinika za unutarnje bolesti, Klini&#x010D;ka bolnica Dubrava, Avenija Gojka &#x0160;u&#x0161;ka 6, 10000 Zagreb, e-po&#x0161;ta: <email xlink:href="biknezevic@gmail.com">biknezevic@gmail.com</email></corresp>
<fn fn-type="con">
<p content-type="fn-title">DOPRINOS AUTORA</p>
<p>K<sc>oncepcija</sc> <sc>ili</sc> <sc>nacrt</sc> <sc>rada</sc>: SM, MB, LP, VEM</p>
<p>P<sc>rikupljanje</sc>, <sc>analiza</sc> <sc>i</sc> <sc>interpretacija</sc> <sc>podataka</sc>: BK</p>
<p>P<sc>isanje</sc> <sc>prve</sc> <sc>verzije</sc> <sc>rada</sc>: BK, MB</p>
<p>K<sc>riti&#x010D;ka</sc> <sc>revizija</sc>: BK, SM, MB, LP, VEM</p>
</fn>
</author-notes>
<pub-date date-type="pub" publication-format="electronic"><month>07</month><year>2026</year></pub-date>
<pub-date date-type="pub" publication-format="print"><month>07</month><year>2026</year></pub-date>
<volume>148</volume>
<issue>5-6</issue>
<fpage>192</fpage>
<lpage>200</lpage>
<permissions>
<copyright-statement>Croatian Medical Association</copyright-statement>
<copyright-year>2026</copyright-year>
<copyright-holder>Croatian Medical Association</copyright-holder>
<license xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" specific-use="CC BY-NC-ND 4.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND) 4.0 License.</license-p></license>
</permissions>
<abstract>
<title>SA&#x017D;ETAK</title>
<p>Upalne bolesti crijeva kroni&#x010D;ne su upalne bolesti &#x010D;ija to&#x010D;na etiologija jo&#x0161; uvijek nije poznata. Imunolo&#x0161;ki, genetski i okoli&#x0161;ni &#x010D;imbenici uz promjene crijevne mikrobiote i intestinalne barijere najvjerojatniji su patogenetski mehanizmi nastanka bolesti. Crijevna propusnost jedan je od bitnih &#x010D;imbenika u nastanku crijevne upale, a povezana je s disbiozom, upalnim odgovorom i promjenama me&#x0111;ustani&#x010D;nih uskih spojeva crijevne epitelne barijere. Klaudini koji su dio obitelji proteina koji &#x010D;ine uske spojeve klju&#x010D;ni su za odr&#x017E;avanje integriteta crijevne barijere i sudjeluju u regulaciji paracelularne propusnosti. Sagledavaju&#x0107;i multifaktorijalnu prirodu bolesti, uloga klaudina u nastanku upalne bolesti crijeva postaje predmet brojnih istra&#x017E;ivanja s obzirom na novija saznanja koja upu&#x0107;uju na to da klaudini nemaju samo ulogu transmembranskih proteina, ve&#x0107; da imaju i brojne druge funkcije te da promjene u izra&#x017E;aju, prostornoj i vremenskoj raspodjeli odre&#x0111;enih klaudina mogu implicirati dosada neprepoznate patofiziolo&#x0161;ke mehanizme odgovorne za nastanak upalnih bolesti crijeva.</p>
</abstract>
<trans-abstract xml:lang="en">
<title>SUMMARY</title>
<p>Inflammatory bowel diseases are chronic disorders of the digestive system, the exact etiology of which is still unknown. Immunological, genetic, and environmental factors, along with changes in the gut microbiota and intestinal barrier, are the most likely pathogenetic mechanisms of disease development. Intestinal permeability is one of the essential factors in the onset of inflammation and is associated with dysbiosis, inflammatory response, and changes in the tight junctions of the intestinal epithelial barrier. Claudins, which are part of the family of proteins that form tight junctions, are crucial for maintaining the integrity of the intestinal barrier and participate in the regulation of paracellular permeability. Considering the multifactorial nature of the disease, the role of claudins in the development of inflammatory bowel disease has become the subject of numerous studies in light of recent findings suggesting that claudins not only serve as transmembrane proteins but also have various other functions, and that changes in the expression, spatial, and temporal distribution of certain claudins may imply previously unrecognized pathophysiological mechanisms responsible for the onset of inflammatory bowel diseases.</p>
</trans-abstract>
<kwd-group kwd-group-type="author"><kwd>Deskriptori UPALNE BOLESTI CRIJEVA &#x2013; imunogija, metabolizam, patologija</kwd><kwd>CRIJEVNA SLUZNICA &#x2013; imunologija, metabolizam, patologija</kwd><kwd>USKI SPOJEVI &#x2013; metabolizam, patologija</kwd><kwd>KLAUDINI &#x2013; metabolizam</kwd><kwd>GASTROINTESTINALNI MIKROBIOM</kwd></kwd-group>
<kwd-group kwd-group-type="translator" xml:lang="en"><title>Descriptors </title><kwd>INFLAMMATORY BOWEL DISEASES &#x2013; immunology, metabolism, pathology</kwd><kwd>INTESTINAL MUCOSA &#x2013; immunology, metabolism, pathology</kwd><kwd>TIGHT JUNCTIONS &#x2013; metabolism, pathology</kwd><kwd>CLAUDINS &#x2013; metabolism</kwd><kwd>GASTROINTESTINAL MICROBIOME</kwd></kwd-group>
</article-meta>
</front>
<body>
<p>Upalne bolesti crijeva (UBC, engl. <italic>inflammatory bowel disease</italic>, IBD) su kroni&#x010D;ne, imunim mehanizmima posredovane bolesti probavnog sustava. Upala mo&#x017E;e zahvatiti bilo koji dio probavne cijevi od usne &#x0161;upljine do anusa, a istodobno s upalnim promjenama crijeva mogu&#x0107;a je i pojavnost izvancrijevnih manifestacija bolesti. (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>) UBC karakteriziraju razdoblja relapsa i remisije te bimodalni obrazac pojave bolesti. Naj&#x010D;e&#x0161;&#x0107;e se pojavljuju u mla&#x0111;oj &#x017E;ivotnoj dobi izme&#x0111;u 20. i 30. godine &#x017E;ivota, no postoji i tzv. <italic>second peak</italic> u dobi izme&#x0111;u 50. i 80. godine &#x017E;ivota. (<xref ref-type="bibr" rid="r2"><italic>2</italic></xref>) Poznata su dva osnovna entiteta UBC-a: ulcerozni kolitis (UK, engl. <italic>ulcerative colitis</italic>, UC) i Crohnova bolest (CB, engl. <italic>Crohn&#x2019; s disease,</italic> CD). Kod 10 &#x2013; 15% bolesnika prisutan je nedeterminirani oblik bolesti, odnosno rije&#x010D; je o bolesnicima koji se s obzirom na klini&#x010D;ke i dijagnosti&#x010D;ke kriterije ne mogu svrstati niti u jedan od osnovnih entiteta. (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>)</p>
<p>Incidencija UBC-a u porastu je u cijelom svijetu. Poznata je povezanost pojavnosti UBC-a sa zapadnja&#x010D;kim stilom &#x017E;ivota i &#x017E;ivotom na sjevernoj Zemljinoj hemisferi. Porast incidencije zabilje&#x017E;en je u cijelom svijetu, najvi&#x0161;e u zemljama u razvoju, no incidencija nastavlja rasti i u razvijenim zemljama, pogotovo me&#x0111;u djecom i starijim dobnim skupinama. Procijenjeno je da oko 0,2% europske populacije boluje od UBC-a. Do sada su zemlje Sjeverne Amerike i sjeverne Europe imale najve&#x0107;u prevalenciju i do nedavno se smatralo da su UBC izrazito rijetke u Africi i Aziji, no u posljednje vrijeme bilje&#x017E;i se porast incidencije i u novoindustrijaliziranim zemljama Azije, Afrike i Latinske Amerike. (<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>-<xref ref-type="bibr" rid="r5"><italic>5</italic></xref>)</p>
<p>Etiologija i patogeneza UBC-a do danas nije u potpunosti razja&#x0161;njena. Smatra se da je za nastanak bolesti odgovorna slo&#x017E;ena interakcija izme&#x0111;u genetskih &#x010D;imbenika, poreme&#x0107;aja imunolo&#x0161;kog odgovora i &#x010D;imbenika okoli&#x0161;a. Istra&#x017E;ivanja su pokazala povezanost nastanka UBC-a s vi&#x0161;e od 160 genskih lokusa, no poznato je da se bolest ne&#x0107;e izraziti kod svih pojedinaca s genetskom predispozicijom. Stoga valja pretpostaviti da genetski rizik ipak u manjoj mjeri nego &#x0161;to se prije smatralo obja&#x0161;njava nastanak bolesti. Intolerancija na vlastiti crijevni mikrobiom u genetski predisponiranih osoba smatra se jednim od presudnih doga&#x0111;aja u nastanku UBC-a. Osim promjena u crijevnoj mikrobioti, zna&#x010D;ajan doprinos nastanku UBC-a ima i pove&#x0107;ana propusnost crijevne barijere uzrokovana promjenama uskih veza izme&#x0111;u enterocita.</p>
<p>Promjene crijevnog mikrobioma, poreme&#x0107;aj integriteta crijevne barijere, smanjeno stvaranje antmikrobnih peptida i sluzi uz pove&#x0107;anu translokaciju bakterija u sluznicu dovode do poreme&#x0107;aja imunolo&#x0161;kog odgovora i pridonose poreme&#x0107;aju fiziolo&#x0161;ke ravnote&#x017E;e koja se naposljetku izra&#x017E;ava kroz nastanak kroni&#x010D;ne crijevne upale. (<xref ref-type="bibr" rid="r6"><italic>6</italic></xref>-<xref ref-type="bibr" rid="r8"><italic>8</italic></xref>)</p>
<p>Intaktna crijevna barijera, &#x0161;tite&#x0107;i organizam od nepovoljnog utjecaja raznih potencijalno &#x0161;tetnih &#x010D;imbenika, odgovorna je za odr&#x017E;avanje homeostaze organizma. Shodno tomu, poreme&#x0107;aji crijevne barijere, disregulacija uskih spojeva i pove&#x0107;ana crijevna propusnost imaju jednu od klju&#x010D;nih uloga u nastanku UBC-a. (<xref ref-type="bibr" rid="r7"><italic>7</italic></xref>) Jedinstveno obilje&#x017E;je UBC-a je nemogu&#x0107;nost odr&#x017E;avanja intaktne crijevne barijere, za &#x0161;to su u fiziolo&#x0161;kim uvjetima odgovorni me&#x0111;ustani&#x010D;ni kompleksi koji se nazivaju uski spojevi (engl. <italic>tight junctions</italic>, TJs). Sve je vi&#x0161;e istra&#x017E;ivanja koja govore da bi klaudini, &#x010D;lanovi obitelji proteina uskih spojeva, mogli imati zamjetnu ulogu u nastanku UBC-a. Naime, zabilje&#x017E;eno je da promjene u njihovom izra&#x017E;aju i/ili lokalizaciji dovode do disfunkcije crijevne barijere te pogoduju imunolo&#x0161;kom poreme&#x0107;aju i nastanku crijevne upale. Ranije se smatralo da klaudini imaju samo funkciju transmembranskih proteina koji reguliraju prolaz iona, vode ili tvari me&#x0111;u stanicama, no novija istra&#x017E;ivanja pokazuju da oni imaju i brojne druge funkcije. U posljednje vrijeme sve se vi&#x0161;e istra&#x017E;ivanja bavi pitanjem sudjeluju li klaudini u adaptivnim ili patolo&#x0161;kim odgovorima kod bolesnika s UBC-om. (<xref ref-type="bibr" rid="r9"><italic>9</italic></xref>) Posebno su zanimljiva opa&#x017E;anja koja govore o postojanju defekta crijevne barijere koji mo&#x017E;e prethoditi samoj pojavi bolesti, odnosno o promjenama crijevne barijere koje su prisutne ve&#x0107; u pretklini&#x010D;koj fazi. U kontekstu sve ve&#x0107;e incidencije bolesti u cijelom svijetu, primarna i sekundarna prevencija UBC-a name&#x0107;u se kao pitanja od posebnog interesa. Kako bi se ostvarili ciljevi u postizanju rane dijagnoze bolesti i prevencije, nu&#x017E;no je bolje razumijevanje slo&#x017E;enih patofiziolo&#x0161;kih mehanizama koji pokre&#x0107;u razvoj bolesti, pogotovo kada razmi&#x0161;ljamo o pretklini&#x010D;koj fazi UBC-a. (<xref ref-type="bibr" rid="r10"><italic>10</italic></xref>, <xref ref-type="bibr" rid="r11"><italic>11</italic></xref>)</p>
<sec sec-type="other1">
<title>Crijevna barijera</title>
<p>Budu&#x0107;i da raste svijest o presudnoj va&#x017E;nosti homeostaze sluznice u o&#x010D;uvanju crijevnog zdravlja, sve je vi&#x0161;e istra&#x017E;ivanja koja se fokusiraju na klini&#x010D;ki zna&#x010D;aj integriteta crijevne barijere te na mehanizme koji dovode do poreme&#x0107;aja homeostaze. (<xref ref-type="bibr" rid="r12"><italic>12</italic></xref>-<xref ref-type="bibr" rid="r14"><italic>14</italic></xref>) Crijevna barijera sastoji se od vi&#x0161;e slojeva. Vanjski sloj sastoji se od sluzi, crijevne mikrobiote i obrambenih bjelan&#x010D;evina kao &#x0161;to su sekretorni imunoglobulin A. (<xref ref-type="bibr" rid="r15"><italic>15</italic></xref>) Ispod vanjskog sloja nalazi se sloj intestinalnih epitelnih stanica koji predstavlja najve&#x0107;u i najva&#x017E;niju barijeru prema vanjskom okoli&#x0161;u. Sloj epitelnih stanica djeluje kao selektivno propusna barijera koja dopu&#x0161;ta apsorpciju hranjivih tvari, vode i elektrolita te istodobno odr&#x017E;ava u&#x010D;inkovitu obranu od intraluminalnih toksina, antigena i crijevne mikrobiote. (<xref ref-type="bibr" rid="r16"><italic>16</italic></xref>) Izme&#x0111;u enterocita nalaze se uski spojevi koji se sastoje od nekoliko transmembranskih i citosolnih proteina kao &#x0161;to su okludin, klaudini, tricelulin, cingulin, spojne adhezijske molekule-A (engl. <italic>junctional adhesion molecule-A</italic>, JAM-A) i <italic>zonula occludens.</italic> (<xref ref-type="bibr" rid="r17"><italic>17</italic></xref>) Proteini koji &#x010D;ine uske spojeve klju&#x010D;ni su za odr&#x017E;avanje cjelovitosti epitelne barijere. Ve&#x0107;ina ovih proteina integralni su membranski proteini koji se prote&#x017E;u u me&#x0111;ustani&#x010D;ne prostore. (<xref ref-type="bibr" rid="r18"><italic>18</italic></xref>) Zajedno s unutarstani&#x010D;nim signalnim proteinima, proteini uskih spojeva aktiviraju brojne stani&#x010D;ne procese koji su odgovorni za odr&#x017E;avanje integriteta intestinalne crijevne barijere i uklju&#x010D;eni su u regulaciju me&#x0111;ustani&#x010D;ne propusnosti. (<xref ref-type="bibr" rid="r19"><italic>19</italic></xref>) Proteini koji formiraju uske spojeve uklju&#x010D;eni su i u regulaciju drugih funkcija stanice poput odr&#x017E;avanja stani&#x010D;ne polarnosti, proliferacije i diferencijacije epitelnih stanica. (<xref ref-type="bibr" rid="r20"><italic>20</italic></xref>) Intestinalna epitelna barijera sadr&#x017E;i i imunolo&#x0161;ke stanice kao &#x0161;to su dendriti&#x010D;ke stanice, T-stanice, B-stanice i makrofage, koji funkcioniraju u bliskoj vezi s intestinalnim epitelnim stanicama i sudjeluju u odr&#x017E;avanju crijevne homeostaze. Ispod epitelnog sloja nalazi se lamina proprija, tanki sloj vezivnog tkiva koji ima klju&#x010D;nu ulogu u odr&#x017E;avanju normalne komunikacije izme&#x0111;u mikrobioma i imunolo&#x0161;kih stanica. (<xref ref-type="bibr" rid="r18"><italic>18</italic></xref>)</p>
<p>Crijevna barijera predstavlja primarno mjesto interakcije izme&#x0111;u organizma i potencijalno &#x0161;tetnih &#x010D;imbenika okoli&#x0161;a te slu&#x017E;i kao prva linija obrane koja sprje&#x010D;ava nekontrolirani prodor antigena kroz sluznicu u dublje slojeve crijeva. (<xref ref-type="bibr" rid="r21"><italic>21</italic></xref>) Integritet crijevne barijere zna&#x010D;ajno je naru&#x0161;en u kontekstu UBC-a. Poreme&#x0107;aj crijevne barijere prvenstveno se mo&#x017E;e pripisati abnormalnostima u pet klju&#x010D;nih elemenata: epitelnim stanicama, stani&#x010D;nim spojevima, sloju sluzi, crijevnom imunolo&#x0161;kom sustavu i komenzalnoj mikrobioti. Zbog slo&#x017E;enih interakcija me&#x0111;u njima, disfunkcija pojedinog &#x010D;imbenika odgovornog za odr&#x017E;avanje integriteta crijevne barijere mo&#x017E;e dovesti do disfunkcije drugog, me&#x0111;usobno mogu pogor&#x0161;ati disfunkciju i time potencijalno uspostaviti za&#x010D;arani krug. Posljedi&#x010D;no, prekid ovog ciklusa postaje klju&#x010D;an za kontrolu napredovanja crijevne upale. (<xref ref-type="bibr" rid="r22"><italic>22</italic></xref>) U paracelularnom prostoru (<xref ref-type="fig" rid="f1">Figure 1</xref>) nalazi se vi&#x0161;e me&#x0111;ustani&#x010D;nih veza me&#x0111;u kojima klaudini imaju glavnu ulogu u o&#x010D;uvanju crijevne barijere i regulaciji crijevne propusnosti. (<xref ref-type="bibr" rid="r17"><italic>17</italic></xref>)</p>
<fig id="f1" position="float" fig-type="figure"><label>Figure 1</label><caption><p>A<sc>natomy</sc> <sc>of</sc> <sc>the</sc> <sc>intestinal</sc> <sc>barrier</sc> (<sc>adapted</sc> <sc>according</sc> <sc>to</sc>: S<sc>uzuki</sc> T. R<sc>egulation</sc> <sc>of</sc> <sc>the</sc> <sc>intestinal</sc> <sc>barrier</sc> <sc>by</sc> <sc>nutrients</sc>: T<sc>he</sc> <sc>role</sc> <sc>of</sc> <sc>tight</sc> <sc>junctions</sc>. A<sc>nim</sc> S<sc>ci</sc> J. 2020;91(1):<sc>e</sc>13357.)&#x2028;ZO-1: zonula occludens; JAM-A: spojna adhezijska molekula A / junctional adhesion molecule &#x2013; A; MLCK: kinaza lakog lanca miozina / myosin light chain kinase</p></caption><graphic xlink:href="LV-148-192-f1"></graphic></fig>
<p>Poreme&#x0107;aj crijevne barijere uz slom tolerancije na vlastitu crijevnu mikrobiotu jedan je od mogu&#x0107;ih mehanizama nastanka UBC-a, no postoje nejasno&#x0107;e oko toga je li poreme&#x0107;aj crijevne barijere primarni ili sekundarni doga&#x0111;aj u nastanku bolesti. U studiji Keita i suradnika koja je prou&#x010D;avala parove blizanaca, a u kojoj je jedan blizanac imao postavljenu dijagnozu CB-a, dok drugi blizanac nije imao histolo&#x0161;kih znakova UBC-a, <italic>ex vivo</italic> analiza uzoraka sluznice crijeva ukazala je na pove&#x0107;anu paracelularnu propusnost kod blizanaca bez dokumentiranih histolo&#x0161;kih promjena u odnosu na kontrolnu skupinu. Studija je potvrdila hipotezu da poreme&#x0107;aj crijevne sluznice mo&#x017E;e predstavljati po&#x010D;etni element u nastanku CB-a te kako pove&#x0107;ana crijevna propusnost kod bra&#x0107;e ili sestara oboljelih od CB-a upu&#x0107;uje na utjecaj genetske predispozicije ili mo&#x017E;e upu&#x0107;ivati na izlo&#x017E;enost istim &#x0161;tetnim &#x010D;initeljima okoli&#x0161;a tijekom djetinjstva. (<xref ref-type="bibr" rid="r23"><italic>23</italic></xref>)</p>
</sec>
<sec sec-type="other2">
<title>Pretklini&#x010D;ka faza upalnih bolesti crijeva</title>
<p>S obzirom na rastu&#x0107;u incidenciju UBC-a u svijetu i s time pove&#x0107;ane tro&#x0161;kove zdravstvenog sustava, nastanak invaliditeta i smanjenje kvalitete &#x017E;ivota oboljelih, rano postavljanje dijagnoze i mogu&#x0107;nost prevencije UBC-a sve se vi&#x0161;e name&#x0107;u kao pitanja od klju&#x010D;nog interesa. Sukladno tomu, raste broj istra&#x017E;ivanja koja su usredoto&#x010D;ena na pretklini&#x010D;ku fazu UBC-a. U fokus istra&#x017E;ivanja name&#x0107;e se potreba za boljim razumijevanjem &#x010D;imbenika rizika koji mogu u budu&#x0107;nosti dovesti do pojave UBC-a (<xref ref-type="fig" rid="f2">Figure 2</xref>), kako bi se bolje sagledale mogu&#x0107;nosti za eventualne preventivne intervencije. Kao i kod drugih imunolo&#x0161;ki posredovanih bolesti, vjeruje se da je po&#x010D;etak UBC-a uvjetovan utjecajem nepovoljnih &#x010D;initelja okoli&#x0161;a kod genetski predisponiranih pojedinaca. Presudni &#x010D;initelji koji pokre&#x0107;u etiopatogenetske mehanizme bolesti, dovode do imunolo&#x0161;kih poreme&#x0107;aja i naposljetku do kroni&#x010D;ne upale nisu jo&#x0161; do kraja razja&#x0161;njeni, no sve je vi&#x0161;e dokaza da ti &#x010D;initelji okoli&#x0161;a djeluju godinama prije pojave prvih simptoma bolesti.</p>
<fig id="f2" position="float" fig-type="figure"><label>Figure 2</label><caption><p>Changes in the intestinal mucosa during the preclinical phase of inflammatory bowel disease</p></caption><graphic xlink:href="LV-148-192-f2"></graphic></fig>
<p>Kako bi se uistinu promijenio prirodni tijek bolesti i sprije&#x010D;ile posljedice kroni&#x010D;ne upale, neizostavno je identificirati presudne biolo&#x0161;ke procese koji dovode do upale te poku&#x0161;ati intervenirati u najranijoj fazi, idealno u pretklini&#x010D;koj, kada jo&#x0161; nije niti do&#x0161;lo do pojave simptoma, sa svrhom medicinske intervencije u najranijoj fazi kako bi se preventivno djelovalo. (<xref ref-type="bibr" rid="r24"><italic>24</italic></xref>)</p>
<p>Istra&#x017E;ivanja koja su prou&#x010D;avala pretklini&#x010D;ku fazu UBC-a upu&#x0107;uju da se doga&#x0111;aji koji prethode pojavi bolesti zbivaju barem dvije godine prije klini&#x010D;kog po&#x010D;etka UBC-a. To razdoblje karakterizirano je subklini&#x010D;kom sustavnom i crijevnom upalom te je obilje&#x017E;eno nespecifi&#x010D;nim simptomima i pove&#x0107;anom potrebom za kori&#x0161;tenjem zdravstvene skrbi. (<xref ref-type="bibr" rid="r11"><italic>11</italic></xref>)</p>
<p>Prospektivna studija koja je uklju&#x010D;ila 3483 zdravih srodnika bolesnika s CD-om u prvom koljenu provedena je s ciljem identifikacije sastava mikrobioma prisutnog u crijevu prije po&#x010D;etka CD-a, kako bi se razjasnilo u kojoj mjeri mikrobni potpis prisutan u razdoblju prije pojave klini&#x010D;kih simptoma predvi&#x0111;a rizik od nastanka CD-a. Istra&#x017E;ivanje je pokazalo da je pove&#x0107;ana zastupljenost sojeva <italic>R. Momenta</italic> i <italic>Blautia</italic> u pozitivnoj korelaciji s rizikom bolesti te da bi ti sojevi mogli zna&#x010D;ajno doprinijeti nastanku CD-a. Smatra se da su te bakterije povezane s poja&#x010D;anom razgradnjom mucina koji ima za&#x0161;titnu funkciju u epitelnoj crijevnoj barijeri. Me&#x0111;u ostalim, ovo je prva studija koja je pokazala da smanjenje roda <italic>Faecalibacterium</italic> mo&#x017E;e upu&#x0107;ivati na pretklini&#x010D;ki potpis CD-a koji se mo&#x017E;e uo&#x010D;iti vi&#x0161;e godina prije po&#x010D;etka bolesti. Posljedi&#x010D;no ovom istra&#x017E;ivanju name&#x0107;e se zanimljivo pitanje: mo&#x017E;emo li intervencijom u mikrobiom, konkretno obnavljanjem soja <italic>Faecalibacterium</italic> tijekom pretklini&#x010D;ke faze UBC-a, pomo&#x0107;i u odgodi ili &#x010D;ak u potpunosti sprije&#x010D;iti razvoj CD-a. (<xref ref-type="bibr" rid="r25"><italic>25</italic></xref>)</p>
</sec>
<sec sec-type="other3">
<title>Epitelna homeostaza i upala crijevne sluznice</title>
<p>Crijevni epitel sastoji se od jednog sloja razli&#x010D;itih specijaliziranih podtipova crijevnih epitelnih stanica (engl. <italic>specialized intestinal epithelial cells</italic>, IECs) kao &#x0161;to su apsortivne stanice, vr&#x010D;aste stanice, Panethove stanice, enteroendokrine stanice, M-stanice i &#x010D;etkaste stanice. Specijalizirane crijevne epitelne stanice nastaju diferencijacijom mati&#x010D;nih epitelnih stanica, funkcionalno se razlikuju i imaju va&#x017E;nu ulogu u odr&#x017E;avanju intestinalne homeostaze. One &#x010D;ine barijeru izme&#x0111;u sadr&#x017E;aja u crijevnom lumenu i lamine proprije te su uklju&#x010D;ene u interakciju izme&#x0111;u mikrobiote i imunolo&#x0161;kih stanica. Stoga poreme&#x0107;aj u diferencijaciji i nastanku funkcionalnih specijaliziranih crijevnih epitelnih stanica igra jednu od bitnih uloga u nastanku UBC-a. Epitelni jednosloj je glavna komponenta crijevne barijere, a mre&#x017E;a koju &#x010D;ine proteini uskih spojeva omogu&#x0107;uje njezino funkcioniranje u vidu za&#x0161;titne fizi&#x010D;ke barijere. Uski spojevi uklju&#x010D;eni su u regulaciju crijevne propusnosti i odr&#x017E;avanje cjelovitosti crijevne barijere, proizvodnju sluzi, prepoznavanje patogena i proizvodnju antimikrobnih peptida koji su nu&#x017E;ni za postojanje u&#x010D;inkovite imunosti. Uski spojevi zatvaraju me&#x0111;ustani&#x010D;ni prostor izme&#x0111;u epitelnih stanica i odvajaju stani&#x010D;nu membranu na apikalnu i bazolateralnu domenu i na taj na&#x010D;in tvore za&#x0161;titnu barijeru protiv &#x0161;tetnih noksi. (<xref ref-type="bibr" rid="r26"><italic>26</italic></xref>) Poznata je povezanost izme&#x0111;u epitelne disfunkcije, abnormalne crijevne propusnosti i upale sluznice crijeva. Poreme&#x0107;aj u funkciji crijevne barijere koji dovodi do pove&#x0107;ane crijevne propusnosti zamije&#x0107;en je kod brojnih intestinalnih i sistemskih bolesti, no najvi&#x0161;e je prou&#x010D;en kod upalnih bolesti crijeva i celijakije. (<xref ref-type="bibr" rid="r27"><italic>27</italic></xref>) Crijevni epitel nije samo kruta fizi&#x010D;ka barijera, ve&#x0107; predstavlja i visokospecijalizirana vrata koja kontroliraju ulazak raznih antigena i tako sudjeluje u odr&#x017E;avanju zdravlja doma&#x0107;ina. Epitel crijeva obilje&#x017E;en je visokom stopom izmjene stanica i u potpunosti se obnavlja unutar samo &#x010D;etiri do pet dana, a neuspjeh koordiniranog obnavljanja stanica mo&#x017E;e uzrokovati te&#x0161;ke defekte crijevne barijere koji dovode do invazije luminalnih antigena i nastanka crijevne upale, &#x0161;to se mo&#x017E;e vidjeti kod bolesnika s CB-om i UK-om. Funkcija crijevne barijere ne ovisi samo o kordiniranoj proliferaciji i apoptozi stanica, ve&#x0107; i o proteinima uskih spojeva. (<xref ref-type="bibr" rid="r14"><italic>14</italic></xref>) Promijenjen izra&#x017E;aj i strukturne promjene proteina uskih spojeva povezane su s nastankom UBC-a. Pokazalo se da protuupalni citokini kao &#x0161;to su faktor nekroze tumora-alfa (engl. <italic>tumor necrosis factor alpha</italic>, TNF-&#x03B1;) i interferon gama (engl. <italic>interferon gamma</italic>, IFN-y) pove&#x0107;avaju propusnost uskih spojeva i induciraju apoptozu specijaliziranih epitelnih stanica, dok lije&#x010D;enje anti-TNF lijekovima dovodi do obnavljanja crijevne propusnosti. (<xref ref-type="bibr" rid="r28"><italic>28</italic></xref>)</p>
</sec>
<sec sec-type="other4">
<title>Uski spojevi (engl. <italic>tight junctions</italic>, TJs)</title>
<p>Intraepitelne veze sastoje se od nekoliko transmembranskih i citosolnih proteina, uklju&#x010D;uju&#x0107;i okludin, klaudin, <italic>zonula occludens</italic>, tricelulin, cingulin i spojne adhezijske molekule koje u me&#x0111;usobnoj interakciji i u interakciji s citoskeletom tvore kompleksnu arhitekturu. Ve&#x0107;ina ovih proteina, osim cingulina i <italic>zonula occludens</italic>, integralni su membranski proteini koji se prote&#x017E;u u paracelularne prostore izme&#x0111;u stanica (<xref ref-type="fig" rid="f3">Figure 3</xref>). TJs imaju klju&#x010D;nu ulogu u odr&#x017E;avanju selektivne permeabilnosti crijevnog epitela i klju&#x010D;ni su za odr&#x017E;avanje stabilnosti epitelne barijere te na taj na&#x010D;in pridonose odr&#x017E;avanju homeostaze organizma. Zahvaljuju&#x0107;i svom smje&#x0161;taju na apikalnoj strani epitelne stanice omogu&#x0107;avaju ograni&#x010D;enje stupnja permeabilnosti crijevnog epitela. Upalni medijatori kao &#x0161;to su INF-y, TNF&#x03B1;, IL 4 (engl. <italic>interleukin 4</italic>, IL 4), IL 13 (engl. <italic>interleukin 13</italic>, IL 13) ili patogeni kao &#x0161;to su enteropatogena <italic>E. coli</italic> i <italic>C. difficile toxin</italic>, pove&#x0107;avaju intestinalnu paracelularnu permeabilnost svojim djelovanjem na uske spojeve. To posti&#x017E;u na vi&#x0161;e na&#x010D;ina, modificiraju&#x0107;i njihovu strukturu i distribuciju ili djeluju&#x0107;i na aktinski citoskelet koji ih podr&#x017E;ava. (<xref ref-type="bibr" rid="r29"><italic>29</italic></xref>-<xref ref-type="bibr" rid="r32"><italic>32</italic></xref>) Poreme&#x0107;aj crijevne permeabilnosti javlja se kod brojnih bolesti i poreme&#x0107;aja, ne samo kod upalnih bolesti crijeva, ve&#x0107; i kod celijakije, sindroma iritabilnog crijeva, bolesti presatka protiv doma&#x0107;ina (engl. <italic>graft versus host disease</italic>, GvHD) i dijabetesa tipa 1. (<xref ref-type="bibr" rid="r27"><italic>27</italic></xref>) Bolesnici s aktivnom Crohnovom bole&#x0161;&#x0107;u pokazuju izrazito oslabljenu funkciju crijevne barijere. Uz prisutnost lokaliziranih lezija epitela, elektronska mikroskopija otkriva da disfunkcionalnost lanaca uskih spojeva doprinosi disfunkciji crijevne barijere. Zamije&#x0107;eno je da u aktivnoj fazi UBC-a postoji zna&#x010D;ajno smanjenje izra&#x017E;aja klaudina -5 i -8 koji inhibiraju propusnost kationa, dok postoji zna&#x010D;ajno povi&#x0161;en izra&#x017E;aj klaudina -2 koji formira pore. Tijekom faze remisije CB-a, TJs proteini gotovo su obnovljeni, a kontrolirana nekroza stanica dovodi do normalizacije funkcije crijevne barijere i povla&#x010D;enja simptoma bolesti. (<xref ref-type="bibr" rid="r22"><italic>22</italic></xref>) Rezultati navedenih istra&#x017E;ivanja ukazuju na utjecaj mikrobiote i potencijalno patogenih bakterija na promjene u izra&#x017E;aju klaudina.</p>
<fig id="f3" position="float" fig-type="figure"><label>Figure 3</label><caption><p>Schematic showing tight junction localization in an epithelial monolayer (adapted according to: Capaldo CT. Claudin Barriers on the Brink: How Conflicting Tissue and Cellular Priorities Drive IBD Pathogenesis. Int J Mol Sci. 2023;24(10).)</p></caption><graphic xlink:href="LV-148-192-f3"></graphic></fig>
</sec>
<sec sec-type="other5">
<title>Klaudini</title>
<p>Klaudini su integralni membranski proteini u epitelnim i endotelnim tkivima kralje&#x017E;njaka (<xref ref-type="table" rid="t1">Table 1</xref>) i pla&#x0161;ta&#x0161;a koji su odgovorni za odr&#x017E;avanje strukture i funkcije uskih spojeva. Prvi ih je identificirao i izolirao Furuse 1998. godine iz tkiva pile&#x0107;e jetre. (<xref ref-type="bibr" rid="r33"><italic>33</italic></xref>, <xref ref-type="bibr" rid="r34"><italic>34</italic></xref>) Iako je poznato da su uski spojevi klju&#x010D;ni za odr&#x017E;avanje integriteta epitelne barijere, to&#x010D;na uloga svih proteina uskih spojeva nije sasvim jasna. Klaudinska obitelj uklju&#x010D;uje 27 proteina. Smatra se da svaki klaudinski podtip ima jedinstvenu funkciju, a kombinacija izra&#x017E;enih klaudinskih podtipova odgovorna je za svojstvo propusnosti svakog pojedinog epitela, ovisno o fiziolo&#x0161;kim zahtjevima. (<xref ref-type="bibr" rid="r33"><italic>33</italic></xref>) Ultrastrukturno, klaudini su dijelovi uskih spojeva koji slu&#x017E;e za kontrolu selektivnih svojstava naboja i veli&#x010D;ine paracelularnog prostora. Reguliraju svojstva intestinalne barijere kao &#x201E;&#x010D;vrsti&#x201C; ili brtveni klaudini i klaudini koji imaju funkciju stvaranja pora. Brtveni klaudini uklju&#x010D;uju klaudine -1, -3, -4, -5, -6, -8,-12, -18 i klaudin -19, dok klaudini pora uklju&#x010D;uju klaudine -2 i -10. (<xref ref-type="bibr" rid="r35"><italic>35</italic></xref>) Brojne su studije istra&#x017E;ivale prostorno-vremensku raspodjelu klaudina u crijevima. Kod ljudi je glasni&#x010D;ka ribonukleinska kiselina (engl. <italic>messenger RNA</italic>, mRNA) klaudina -1, -2, -7 i -15 otkrivena du&#x017E; cijele osi crijevnog trakta. Pove&#x0107;an izra&#x017E;aj klaudina -5 zabilje&#x017E;en je u duodenumu, dok klaudini -3, -4, -7 i -8 pokazuju pove&#x0107;an izra&#x017E;aj u epitelu distalnoga debelog crijeva. (<xref ref-type="bibr" rid="r36"><italic>36</italic></xref>) U crijevima odraslih mi&#x0161;eva i &#x0161;takora, analiza lan&#x010D;anom reakcijom polimerazom u stvarnom vremenu (engl. <italic>real-time polymerasce chain reaction</italic>, RT-PCR) identificirala je izra&#x017E;aj klaudina -1, -2, -3, -4, -5, -7, -8, - 9, -10, -11, -12, -13, -14, -15, -17 i -18, dok klaudini - 6, -16,-19, -22 i -24 nisu otkriveni. U crijevima je najvi&#x0161;e izra&#x017E;ena mRNA klaudina -2, -3,-7 i -15. (<xref ref-type="bibr" rid="r37"><italic>37</italic></xref>-<xref ref-type="bibr" rid="r39"><italic>39</italic></xref>) Zamije&#x0107;eno je i da se specifi&#x010D;na organizacija klaudina razlikuje tijekom &#x017E;ivota te da je u odraslim specijaliziranim crijevnim epitelnim stanicama razli&#x010D;ita od one u crijevima u razvoju. Tako je u mi&#x0161;eva izra&#x017E;aj mRNA klaudina -1, -2, -5 i -8 od 1. do 90. dana nakon ro&#x0111;enja nizak, dok se izra&#x017E;aj klaudina -19 otkriva isklju&#x010D;ivo od 1. do 14. dana nakon poroda. Klaudin -2 koji stvara pore pri ro&#x0111;enju je izra&#x017E;en du&#x017E; cijele crijevne kripto-luminalne osi, a 90 dana nakon ro&#x0111;enja postaje ograni&#x010D;en na bazu kripte. Sve ve&#x0107;e razine crijevnoga epitelnog klaudina -3, -4, -7 i -15 identificirane su u sazrijevaju&#x0107;em crijevu nakon ro&#x0111;enja. (<xref ref-type="bibr" rid="r37"><italic>37</italic></xref>) Na stani&#x010D;noj razini, klaudini mogu biti usmjereni isklju&#x010D;ivo na uske spojeve ili se nalaze i na lateralnoj membrani polariziranih epitelnih stanica. Klaudini -2, -8, -10, -15 i -18 ograni&#x010D;eni su na uske spojeve, a klaudini -1, -3, -4, -5 i -7 usmjereni su na lateralnu plazma membranu. Smatra se da lateralni izra&#x017E;aj klaudina -7 u specijaliziranim epitelnim stanicama ima signalna svojstva koja utje&#x010D;u na odr&#x017E;avanje interakcija izvanstani&#x010D;nog matriksa, diferencijacije i homeostaze stanica. (<xref ref-type="bibr" rid="r40"><italic>40</italic></xref>) Funkcija klaudina povezanih s bo&#x010D;nom membranom nije sasvim razja&#x0161;njena. Pretpostavlja se i da bi ti klaudini mogli funkcionirati kao rezervoar za klaudine povezane s uskim spojevima tijekom dinami&#x010D;kog preoblikovanja spojnog proteinskog kompleksa, no oni bi mogli imati i signalnu funkciju i tako sudjelovati u kontroli crijevne epitelne homeostaze. (<xref ref-type="bibr" rid="r35"><italic>35</italic></xref>)</p>
<table-wrap id="t1" position="float">
<label>Table 1</label><caption><title>Expression of claudins in the gastrointestinal and respiratory tracts and other epithelial tissues of mammals (adopted according to: G&#x00FC;nzel D, Yu AS. Claudins and the modulation of tight junction permeability. Physiol Rev. 2013;93(2):525-569).</title>
</caption>
<table frame="hsides" rules="groups">
<col width="46.34%"/>
<col width="53.66%"/>
<thead>
<tr>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.75pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Tkivo / Tissue</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">Klaudini / Claudin</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">&#x017D;eludac / Stomach</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">3, 4, 5, 12, 18, 23</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Crijevo / Intestine</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">1&#x2013;5, 7, 8, 10, 12, 13 (glodavac), 15, 18-2, 20, 21, 23</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Jetra / Liver</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">1&#x2013;3, 5&#x2013;9, 14</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">&#x017D;u&#x010D;ni mjehur / Gall bladder</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">1&#x2013;4,10 &gt; 7, 8</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Di&#x0161;ni putevi / Respiratory tract</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">1, 3&#x2013;5, 7, 10, 18-1 (proksimalno); 3&#x2013;5, 7, 8, 15, 18-1 (distalno)</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Epidermis / Epidermis</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">1, 4, 7 &gt; 3, 5, 8, 11, 12, 17</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Oko / Eye</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">1, 4, 7 (ro&#x017E;nica i konjunktiva); 10 (konjunktiva)</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">&#x017D;lijezda slinovnica<break/>/ Salivary gland</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">10 &gt; 1, 2, 3, 4, 7, 8, 12</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Mlije&#x010D;na &#x017E;lijezda<break/>/ Mammary gland</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">1&#x2013;5, 7, 8, 15, 16</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Okusni pupoljak / Taste bud</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">4, 6, 7, 8</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Egzokrini pankreas / Exocrine pancreas</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">1&#x2013;5, 7</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Retinalni pigmentni epitel / Retinal pigment epithelium</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">19 &gt; 3, 10 (ljudski); 1 &gt; 3 (glodavac)</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Koroidni pleksus / Choroid plexus</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">1, 2, 5, 11</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Pu&#x017E;nica / Cochlea</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">1, 2, 3, 8, 9, 10, 11, 12, 14, 18</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Jajnik / Ovary</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">1, 5</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Prostata / Prostate</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">1, 3, 4, 5, 7, 8, 10</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Epididimis / Epididymis</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">4, 7 &gt; 2, 5, 10</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Sjemenski kanali&#x0107;i / Seminiferous tubule</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">3, 5, 11</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt" scope="row">Mokra&#x0107;ni mjehur / Urinary bladder</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.75pt">4, 8, 12</td>
</tr>
</tbody></table></table-wrap>
<p>Kod pacijenata s UBC-om primije&#x0107;ene su promjene u izra&#x017E;aju odre&#x0111;enih klaudina ovisne o aktivnosti bolesti, &#x010D;ime su odre&#x0111;eni &#x010D;lanovi obitelji klaudina postali potencijalni novi terapijski ciljevi.</p>
<p>Upala sluznice u akutnom kolitisu, enteritisu i kroni&#x010D;nim upalnim bolestima crijeva naru&#x0161;ava epitelnu barijeru, &#x0161;to dovodi do izlaganja lamine proprije luminalnim antigenima i mikrobnim agensima koji dodatno doprinose upalnom odgovoru i o&#x0161;te&#x0107;enju crijevne barijere. O&#x0161;te&#x0107;enje crijevne barijere nastaje kao posljedica odgovora na upalne medijatore i na protuupalno kretanje imunolo&#x0161;kih stanica prema mjestu upale. (<xref ref-type="bibr" rid="r41"><italic>41</italic></xref>)</p>
<p>Nekoliko istra&#x017E;ivanja prou&#x010D;avalo je utjecaj medijatora upale na proteine uskih spojeva. Pove&#x0107;an izra&#x017E;aj klaudina -1, -2 i -18 te smanjen izra&#x017E;aj klaudina -3, -4 i -7 primije&#x0107;en je kod UK-a, dok je kod CB-a primije&#x0107;en pove&#x0107;an izra&#x017E;aj klaudina -1 i -2 uz smanjen izra&#x017E;aj crijevnoga epitelnog klaudina -3, -5, - 8, i -12. Izmjenjen profil klaudina u uskim spojevima kao odgovor na upalu povezan je s poreme&#x0107;ajem paracelularnog transporta, &#x0161;to dovodi do promjene funkcije epitelne barijere. Zamjena klaudina koji tvore crijevnu barijeru s klaudinima koji tvore pore dovodi do poreme&#x0107;aja kretanja teku&#x0107;ine i iona u stanice, &#x0161;to se izra&#x017E;ava kroz simptome bolesti kao &#x0161;to je proljev. Promjene u razini klaudina tijekom upale ne dovode samo do promjene svojstava crijevne barijere, nego su povezane i s poreme&#x0107;ajem imunolo&#x0161;koga za&#x0161;titnog odgovora doma&#x0107;ina. Zabilje&#x017E;eno je da se izra&#x017E;aj klaudina -2, koji je u fiziolo&#x0161;kom stanju prisutan u proliferativnim epitelnim stanicama baze kripte, tijekom mukozne upale pove&#x0107;ava u stanicama te se njegov izra&#x017E;aj &#x0161;iri i izvan proliferativnih stanica baze kripte u kolonu. Tako&#x0111;er, <italic>in vitro</italic> analize zabilje&#x017E;ile su pove&#x0107;an izra&#x017E;aj klaudina -2 kao odgovor na izlo&#x017E;enost proinflamatornim citokinima TH1 i TH2. Kod bolesnika s CB-om zabilje&#x017E;en je povi&#x0161;en izra&#x017E;aj klaudina -2 uz smanjen izra&#x017E;aj klaudina -8. Povi&#x0161;en izra&#x017E;aj klaudina -2 povezan je s pove&#x0107;anom pracelularnom propusno&#x0161;&#x0107;u, no ima i utjecaj na obrambenu imunosnu funkciju doma&#x0107;ina. Uloga klaudina -2 u osiguravanju mehani&#x010D;ke za&#x0161;titne barijere nije potpuno jasna, no neizravni mehanizmi kojima klaudin -2 posti&#x017E;e za&#x0161;titni u&#x010D;inak uklju&#x010D;uje poja&#x010D;anu sintezu transformiraju&#x0107;eg &#x010D;imbenika beta (engl. <italic>transforming growth factor beta</italic>, TGF-&#x03B2;), koja potiskuje imunolo&#x0161;ki odgovor inhibicijom upalnih posrednika kao &#x0161;to su nuklearni &#x010D;imbenik kapa B (engl. <italic>nuclear factor kappa-light-chain-enhancer of activated B cells</italic>, NF-&#x03BA;B) i prenositelj signala i aktivator transkripcije 3 (engl. <italic>signal transducer and activator of transcription 3</italic>, STAT-3).</p>
<p>NF-&#x03BA;B i STAT-3. U eksperimentalnim modelima, mi&#x0161;evi koji nemaju STAT-6 (engl. <italic>signal transducer and -6 activator of transcription 6</italic>, STAT) u crijevnom epitelu manje su osjetljivi na kolitis induciran oksazolonom, &#x0161;to je tako&#x0111;er povezano sa smanjenim izra&#x017E;ajem klaudina -2 i stvaranjem TH2 citokina u debelom crijevu i upalnih medijatora. (<xref ref-type="bibr" rid="r35"><italic>35</italic></xref>, <xref ref-type="bibr" rid="r41"><italic>41</italic></xref>)</p>
<p>Nedavno su objavljeni rezultati istra&#x017E;ivanja koje je prou&#x010D;avalo molekularnu integraciju izme&#x0111;u kolitisa, cijeljenja sluznice i karcinoma povezanog s kolitisom (engl. <italic>colitis-associated cancer</italic>, CAC). Cilj ispitivanja bio je razjasniti ulogu klaudina -2 u nastanku karcinoma povezanog s kolitisom. Studija je izvijestila o neo&#x010D;ekivanom otkri&#x0107;u da poja&#x010D;an izra&#x017E;aj klaudina -2 &#x0161;titi od karcinoma povezanog s kolitisom, neovisno o aktivnosti kolitisa, te da za&#x0161;titna uloga klaudina -2 proizlazi iz njegove do sada nepotpuno razja&#x0161;njenje uloge u cijeljenju sluznice. (<xref ref-type="bibr" rid="r42"><italic>42</italic></xref>)</p>
<p>Studija &#x010C;u&#x017E;i&#x0107; i suradnika provedena je s ciljem istra&#x017E;ivanja izra&#x017E;aja klaudina kod bolesnika s UBC-om i dva razli&#x010D;ita &#x017E;ivotinjska modela UBC-a. Uzorci ljudskog kolona kori&#x0161;teni za izolaciju mononuklearnih stanica lamine proprije (engl. <italic>lamina propria mononuclear cells</italic>, LPMCs) uklju&#x010D;ivali su uzorke kirur&#x0161;ke resekcije i biopsije sluznice pacijenata s UBC-om, uklju&#x010D;uju&#x0107;i UK i CB, kontrolne uzorke ljudskog kolona dobivene od pacijenata koji su podvrgnuti resekciji kolona zbog karcinoma, dok su &#x017E;ivotinjski modeli uklju&#x010D;ivali kolitis uzrokovan natrijevim dekstran sulfatom i adoptivni kolitis izazvan prijenosom CD4++CD25-CD62L+ T-limfocita u imunodeficijentne mi&#x0161;eve. Prou&#x010D;avan je izra&#x017E;aj klaudina -1, -2, -3, -4 i -8 metodama imunohistokemije i RT-PCR-om, <italic>western blotom</italic> i proto&#x010D;nom citometrijom. Glavni su zaklju&#x010D;ci ovog istra&#x017E;ivanja da klaudini nisu izra&#x017E;eni samo na povr&#x0161;ini epitelnih stanica, ve&#x0107; se nalaze i u drugim tipovima stanica, kao &#x0161;to su mezodermalne stanice, te da se internaliziraju prema jezgri epitelnih stanica. (<xref ref-type="bibr" rid="r43"><italic>43</italic></xref>)</p>
<p>Rezultati spomenutog istra&#x017E;ivanja ukazuju kako je mogu&#x0107;e da klaudini imaju &#x0161;iru ulogu u etiopatogenezi kroni&#x010D;ne crijevne upale, a ne samo ulogu u regulaciji uskih veza izme&#x0111;u epitelnih stanica.</p>
<p>Prema ranijim istra&#x017E;ivanjima klaudini su smatrani samo dijelovima uskih spojeva neophodnim za formiranje fizi&#x010D;ke crijevne barijere, a novija istra&#x017E;ivanja prikazuju ih u sasvim novom svjetlu i upu&#x0107;uju da oni vjerojatno imaju brojne druge slo&#x017E;ene funkcije te se name&#x0107;u pitanja mogu li promjene u izra&#x017E;aju klaudina u razli&#x010D;itim stanicama sluznice te njihova internalizacija pomo&#x0107;i u otkrivanju rane faze, odnosno faze prije nastupa klini&#x010D;kih znakova i simptoma bolesti sa svojstvom biomarkera ili potencijalne mete u prevenciji i ranom lije&#x010D;enju UBC-a.</p>
<p>Istra&#x017E;ivanje Zammarchi i suradnika prou&#x010D;avalo je lokalizaciju neutrofila u crijevnom epitelu i lamini propriji te izra&#x017E;aj klaudina -2 kao potencijalne nove prediktore ishoda bolesti kod pacijenata s UBC-om. U istra&#x017E;ivanju je zabilje&#x017E;eno da prisutnost neutrofila u epitelu te slab do jak izra&#x017E;aj klaudina -2 mo&#x017E;e upu&#x0107;ivati na pove&#x0107;an rizik relapsa bolesti kod pacijenta u endoskopskoj i histolo&#x0161;koj remisiji. Ova saznanja mogu potencijalno doprinijeti prepoznavanju pacijenata kod kojih je potrebno promijeniti terapijski pristup te personalizirati terapijske opcije kako bi se sprije&#x010D;io relaps bolesti. Jednako tako, ovo istra&#x017E;ivanje upu&#x0107;uje na promjenu izra&#x017E;aja klaudina -2 koji bi mogao predstavljati do sada neprepoznati patogeni mehanizam koji se doga&#x0111;a i prije pojave endoskopski vidljivih promjena sluznice crijeva. (<xref ref-type="bibr" rid="r44"><italic>44</italic></xref>)</p>
</sec>
<sec sec-type="other6">
<title>Zaklju&#x010D;ak</title>
<p>Poreme&#x0107;aj integriteta crijevne barijere jedan je od zna&#x010D;ajnih patofiziolo&#x0161;kih mehanizama u nastanku UBC-a. Intaktni epitelni uski spojevi klju&#x010D;ni su za odr&#x017E;avanje crijevne homeostaze i integriteta epitelne barijere, stoga poreme&#x0107;aji proteina uskih spojeva imaju bitnu ulogu u nastanku UBC-a. Nedavno provedene studije govore u prilog hipoteze kako klaudini osim osiguranja integriteta crijevne barijere i regulacije uskih spojeva imaju i druge funkcije. Primije&#x0107;eno je da klaudini nisu smje&#x0161;teni samo u uskim spojevima, nego se nalaze i u citoplazmi i unutar jezgri epitelnih stanica te da su tako&#x0111;er izra&#x017E;eni i u drugim stanicama crijevne sluznice. Promjene u izra&#x017E;aju i/ili lokalizaciji klaudina dovode do disfunkcije crijevne barijere, pogoduju imunolo&#x0161;kom poreme&#x0107;aju i nastanku UBC-a. Dostupne terapijske opcije za UBC primarno su usredoto&#x010D;ene na suzbijanje upale i trenutno nema prevencijske i/ili terapijske intervencije koja bi specifi&#x010D;no djelovala na o&#x010D;uvanje i obnavljanje integriteta crijevne barijere. Utjecaj na promjenu izra&#x017E;aja klaudina u crijevnoj sluznici mogao bi biti jedan od klju&#x010D;nih &#x010D;imbenika u stvaranju novih terapijskih strategija u lije&#x010D;enju UBC-a. Prema rezultatima novijih istra&#x017E;ivanja promjene izra&#x017E;aja klaudina u crijevnoj sluznici imaju potencijal biomarkera i budu&#x0107;a istra&#x017E;ivanja &#x0107;e rasvijetliti njihovu ulogu kao potencijalne mete u prevenciji i cijeljenju upale. Istra&#x017E;ivanja izra&#x017E;aja, prostorne i vremenske raspodjele klaudina kao i njihovog utjecaja na imunolo&#x0161;ki odgovor mogu voditi do boljeg razumijevanja same patogeneze UBC-a.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict">
<p content-type="fn-title">INFORMACIJE O SUKOBU INTERESA</p>
<p>Autori nisu deklarirali sukob interesa relevantan za ovaj rad.</p>
</fn>
<fn fn-type="financial-disclosure">
<p content-type="fn-title">INFORMACIJA O FINANCIRANJU</p>
<p>Za ovaj &#x010D;lanak nisu primljena financijska sredstva.</p>
</fn>
</fn-group>
<ref-list>
<title>LITERATURA</title>
<ref id="r1"><label>1</label><mixed-citation publication-type="other">Grubeli&#x0107; Ravi&#x0107; K, Vuceli&#x0107; B. Definicije vezane za upalne bolesti crijeva. U: Vuceli&#x0107; B, ur. Upalne bolesti crijeva. Zagreb: Medicinska naklada; 2019, str. 9&#x2013;17.</mixed-citation></ref>
<ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gajendran</surname><given-names>M</given-names></name><name><surname>Loganathan</surname><given-names>P</given-names></name><name><surname>Jimenez</surname><given-names>G</given-names></name><name><surname>Catinella</surname><given-names>AP</given-names></name><name><surname>Ng</surname><given-names>N</given-names></name><name><surname>Umapathy</surname><given-names>C</given-names></name><etal/></person-group> <article-title>Acomprehensive review and update on ulcerative colitis.</article-title> <source>Dis Mon</source>. <year>2019</year>;<volume>65</volume>(<issue>12</issue>):<elocation-id>100851</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.disamonth.2019.02.004</pub-id><pub-id pub-id-type="pmid">30837080</pub-id></mixed-citation></ref>
<ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agrawal</surname><given-names>M</given-names></name><name><surname>Jess</surname><given-names>T</given-names></name></person-group>. <article-title>Implications of the changing epidemiology of inflammatory bowel disease in a changing world.</article-title> <source>United European Gastroenterol J</source>. <year>2022</year>;<volume>10</volume>(<issue>10</issue>):<fpage>1113</fpage>&#x2013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1002/ueg2.12317</pub-id><pub-id pub-id-type="pmid">36251359</pub-id></mixed-citation></ref>
<ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>G&#x00F6;nczi</surname><given-names>L</given-names></name><name><surname>Lakatos</surname><given-names>PL</given-names></name><name><surname>Burisch</surname><given-names>J</given-names></name></person-group>. <article-title>The Burden of Inflammatory Bowel Disease in Europe in 2020.</article-title> <source>J Crohns Colitis</source>. <year>2021</year>;<volume>15</volume>(<issue>9</issue>):<fpage>1573</fpage>&#x2013;<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1093/ecco-jcc/jjab029</pub-id><pub-id pub-id-type="pmid">33582812</pub-id></mixed-citation></ref>
<ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Berre</surname><given-names>C</given-names></name><name><surname>Honap</surname><given-names>S</given-names></name><name><surname>Peyrin-Biroulet</surname><given-names>L</given-names></name></person-group>. <article-title>Ulcerative colitis.</article-title> <source>Lancet</source>. <year>2023</year>;<volume>402</volume>(<issue>10401</issue>):<fpage>571</fpage>&#x2013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(23)00966-2</pub-id><pub-id pub-id-type="pmid">37573077</pub-id></mixed-citation></ref>
<ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dixon</surname><given-names>LJ</given-names></name><name><surname>Kabi</surname><given-names>A</given-names></name><name><surname>Nickerson</surname><given-names>KP</given-names></name><name><surname>McDonald</surname><given-names>C</given-names></name></person-group>. <article-title>Combinatorial effects of diet and genetics on inflammatory bowel disease pathogenesis.</article-title> <source>Inflamm Bowel Dis</source>. <year>2015</year>;<volume>21</volume>(<issue>4</issue>):<fpage>912</fpage>&#x2013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1097/MIB.0000000000000289</pub-id><pub-id pub-id-type="pmid">25581832</pub-id></mixed-citation></ref>
<ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramos</surname><given-names>GP</given-names></name><name><surname>Papadakis</surname><given-names>KA</given-names></name></person-group>. <article-title>Mechanisms of Disease: Inflammatory Bowel Diseases.</article-title> <source>Mayo Clin Proc</source>. <year>2019</year>;<volume>94</volume>(<issue>1</issue>):<fpage>155</fpage>&#x2013;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1016/j.mayocp.2018.09.013</pub-id><pub-id pub-id-type="pmid">30611442</pub-id></mixed-citation></ref>
<ref id="r8"><label>8</label><mixed-citation publication-type="other">Bani&#x0107; M. Patogeneza upalnih bolesti crijeva. U: Vuceli&#x0107; B, ur. Upalne bolesti crijeva. Zagreb: Medicinska naklada; 2019, str. 117&#x2013;37.</mixed-citation></ref>
<ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capaldo</surname><given-names>CT</given-names></name></person-group>. <article-title>Claudin Barriers on the Brink: How Conflicting Tissue and Cellular Priorities Drive IBD Pathogenesis.</article-title> <source>Int J Mol Sci</source>. <year>2023</year>;<volume>24</volume>(<issue>10</issue>): <pub-id pub-id-type="doi">10.3390/ijms24108562</pub-id><pub-id pub-id-type="pmid">37239907</pub-id></mixed-citation></ref>
<ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vivinus-N&#x00E9;bot</surname><given-names>M</given-names></name><name><surname>Frin-Mathy</surname><given-names>G</given-names></name><name><surname>Bzioueche</surname><given-names>H</given-names></name><name><surname>Dainese</surname><given-names>R</given-names></name><name><surname>Bernard</surname><given-names>G</given-names></name><name><surname>Anty</surname><given-names>R</given-names></name><etal/></person-group> <article-title>Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation.</article-title> <source>Gut</source>. <year>2014</year>;<volume>63</volume>(<issue>5</issue>):<fpage>744</fpage>&#x2013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1136/gutjnl-2012-304066</pub-id><pub-id pub-id-type="pmid">23878165</pub-id></mixed-citation></ref>
<ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudbaek</surname><given-names>JJ</given-names></name><name><surname>Agrawal</surname><given-names>M</given-names></name><name><surname>Torres</surname><given-names>J</given-names></name><name><surname>Mehandru</surname><given-names>S</given-names></name><name><surname>Colombel</surname><given-names>JF</given-names></name><name><surname>Jess</surname><given-names>T</given-names></name></person-group>. <article-title>Deciphering the different phases of preclinical inflammatory bowel disease.</article-title> <source>Nat Rev Gastroenterol Hepatol</source>. <year>2024</year>;<volume>21</volume>(<issue>2</issue>):<fpage>86</fpage>&#x2013;<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1038/s41575-023-00854-4</pub-id><pub-id pub-id-type="pmid">37950021</pub-id></mixed-citation></ref>
<ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stange</surname><given-names>EF</given-names></name><name><surname>Schroeder</surname><given-names>BO</given-names></name></person-group>. <article-title>Microbiota and mucosal defense in IBD: an update.</article-title> <source>Expert Rev Gastroenterol Hepatol</source>. <year>2019</year>;<volume>13</volume>(<issue>10</issue>):<fpage>963</fpage>&#x2013;<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1080/17474124.2019.1671822</pub-id><pub-id pub-id-type="pmid">31603356</pub-id></mixed-citation></ref>
<ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoultz</surname><given-names>I</given-names></name><name><surname>Keita</surname><given-names>&#x00C5;V</given-names></name></person-group>. <article-title>Cellular and Molecular Therapeutic Targets in Inflammatory Bowel Disease-Focusing on Intestinal Barrier Function.</article-title> <source>Cells</source>. <year>2019</year>;<volume>8</volume>(<issue>2</issue>): <pub-id pub-id-type="doi">10.3390/cells8020193</pub-id><pub-id pub-id-type="pmid">30813280</pub-id></mixed-citation></ref>
<ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martini</surname><given-names>E</given-names></name><name><surname>Krug</surname><given-names>SM</given-names></name><name><surname>Siegmund</surname><given-names>B</given-names></name><name><surname>Neurath</surname><given-names>MF</given-names></name><name><surname>Becker</surname><given-names>C</given-names></name></person-group>. <article-title>Mend Your Fences: The Epithelial Barrier and its Relationship With Mucosal Immunity in Inflammatory Bowel Disease.</article-title> <source>Cell Mol Gastroenterol Hepatol</source>. <year>2017</year>;<volume>4</volume>(<issue>1</issue>):<fpage>33</fpage>&#x2013;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcmgh.2017.03.007</pub-id><pub-id pub-id-type="pmid">28560287</pub-id></mixed-citation></ref>
<ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keita</surname><given-names>AV</given-names></name><name><surname>S&#x00F6;derholm</surname><given-names>JD</given-names></name></person-group>. <article-title>The intestinal barrier and its regulation by neuroimmune factors.</article-title> <source>Neurogastroenterol Motil</source>. <year>2010</year>;<volume>22</volume>(<issue>7</issue>):<fpage>718</fpage>&#x2013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2982.2010.01498.x</pub-id><pub-id pub-id-type="pmid">20377785</pub-id></mixed-citation></ref>
<ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Groschwitz</surname><given-names>KR</given-names></name><name><surname>Hogan</surname><given-names>SP</given-names></name></person-group>. <article-title>Intestinal barrier function: molecular regulation and disease pathogenesis.</article-title> <source>J Allergy Clin Immunol</source>. <year>2009</year>;<volume>124</volume>(<issue>1</issue>):<fpage>3</fpage>&#x2013;<lpage>20, quiz 1&#x2013;2</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaci.2009.05.038</pub-id><pub-id pub-id-type="pmid">19560575</pub-id></mixed-citation></ref>
<ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>T</given-names></name></person-group>. <article-title>Regulation of the intestinal barrier by nutrients: The role of tight junctions.</article-title> <source>Anim Sci J</source>. <year>2020</year>;<volume>91</volume>(<issue>1</issue>):<elocation-id>e13357</elocation-id>. <pub-id pub-id-type="doi">10.1111/asj.13357</pub-id><pub-id pub-id-type="pmid">32219956</pub-id></mixed-citation></ref>
<ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chelakkot</surname><given-names>C</given-names></name><name><surname>Ghim</surname><given-names>J</given-names></name><name><surname>Ryu</surname><given-names>SH</given-names></name></person-group>. <article-title>Mechanisms regulating intestinal barrier integrity and its pathological implications.</article-title> <source>Exp Mol Med</source>. <year>2018</year>;<volume>50</volume>(<issue>8</issue>):<fpage>1</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/s12276-018-0126-x</pub-id><pub-id pub-id-type="pmid">30115904</pub-id></mixed-citation></ref>
<ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>B</given-names></name><name><surname>Moon</surname><given-names>KM</given-names></name><name><surname>Kim</surname><given-names>CY</given-names></name></person-group>. <article-title>Tight Junction in the Intestinal Epithelium: Its Association with Diseases and Regulation by Phytochemicals.</article-title> <source>J Immunol Res</source>. <year>2018</year>;<volume>2018</volume>:<elocation-id>2645465</elocation-id>. <pub-id pub-id-type="doi">10.1155/2018/2645465</pub-id><pub-id pub-id-type="pmid">30648119</pub-id></mixed-citation></ref>
<ref id="r20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farkas</surname><given-names>AE</given-names></name><name><surname>Capaldo</surname><given-names>CT</given-names></name><name><surname>Nusrat</surname><given-names>A</given-names></name></person-group>. <article-title>Regulation of epithelial proliferation by tight junction proteins.</article-title> <source>Ann N Y Acad Sci</source>. <year>2012</year>;<volume>1258</volume>:<fpage>115</fpage>&#x2013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1111/j.1749-6632.2012.06556.x</pub-id><pub-id pub-id-type="pmid">22731724</pub-id></mixed-citation></ref>
<ref id="r21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bani&#x0107;</surname><given-names>M</given-names></name><name><surname>Mustapi&#x0107;</surname><given-names>S</given-names></name><name><surname>Kne&#x017E;evi&#x0107;</surname><given-names>B</given-names></name><name><surname>Kardum</surname><given-names>D</given-names></name><name><surname>Babi&#x0107;</surname><given-names>&#x017D;</given-names></name><name><surname>Erakovi&#x0107; Haber</surname><given-names>V</given-names></name></person-group>. <article-title>Imunobiologija crijevne sluznice: od lokalne imunosti i mikrobioma do zglobne upale.</article-title> <source>Reumatizam</source>. <year>2023</year>;<volume>70</volume> <supplement>Supl 1</supplement>:<fpage>1</fpage>&#x2013;<lpage>18</lpage>.</mixed-citation></ref>
<ref id="r22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Yue</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Tian</surname><given-names>C</given-names></name><name><surname>Wei</surname><given-names>D</given-names></name><etal/></person-group> <article-title>Restore Intestinal Barrier Integrity: An Approach for Inflammatory Bowel Disease Therapy.</article-title> <source>J Inflamm Res</source>. <year>2024</year>;<volume>17</volume>:<fpage>5389</fpage>&#x2013;<lpage>413</lpage>. <pub-id pub-id-type="doi">10.2147/JIR.S470520</pub-id><pub-id pub-id-type="pmid">39161679</pub-id></mixed-citation></ref>
<ref id="r23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keita</surname><given-names>&#x00C5;V</given-names></name><name><surname>Lindqvist</surname><given-names>CM</given-names></name><name><surname>&#x00D6;st</surname><given-names>&#x00C5;</given-names></name><name><surname>Magana</surname><given-names>CDL</given-names></name><name><surname>Schoultz</surname><given-names>I</given-names></name><name><surname>Halfvarson</surname><given-names>J</given-names></name></person-group>. <article-title>Gut Barrier Dysfunction-A Primary Defect in Twins with Crohn&#x2019;s Disease Predominantly Caused by Genetic Predisposition.</article-title> <source>J Crohns Colitis</source>. <year>2018</year>;<volume>12</volume>(<issue>10</issue>):<fpage>1200</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1093/ecco-jcc/jjy045</pub-id><pub-id pub-id-type="pmid">29659773</pub-id></mixed-citation></ref>
<ref id="r24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torres</surname><given-names>J</given-names></name><name><surname>Burisch</surname><given-names>J</given-names></name><name><surname>Riddle</surname><given-names>M</given-names></name><name><surname>Dubinsky</surname><given-names>M</given-names></name><name><surname>Colombel</surname><given-names>JF</given-names></name></person-group>. <article-title>Preclinical disease and preventive strategies in IBD: perspectives, challenges and opportunities.</article-title> <source>Gut</source>. <year>2016</year>;<volume>65</volume>(<issue>7</issue>):<fpage>1061</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1136/gutjnl-2016-311785</pub-id><pub-id pub-id-type="pmid">27196600</pub-id></mixed-citation></ref>
<ref id="r25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raygoza Garay</surname><given-names>JA</given-names></name><name><surname>Turpin</surname><given-names>W</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Smith</surname><given-names>MI</given-names></name><name><surname>Goethel</surname><given-names>A</given-names></name><name><surname>Griffiths</surname><given-names>AM</given-names></name><etal/></person-group> <article-title>Gut Microbiome Composition Is Associated With Future Onset of Crohn&#x2019;s Disease in Healthy First-Degree Relatives.</article-title> <source>Gastroenterology</source>. <year>2023</year>;<volume>165</volume>(<issue>3</issue>):<fpage>670</fpage>&#x2013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1053/j.gastro.2023.05.032</pub-id><pub-id pub-id-type="pmid">37263307</pub-id></mixed-citation></ref>
<ref id="r26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coskun</surname><given-names>M</given-names></name></person-group>. <article-title>Intestinal epithelium in inflammatory bowel disease.</article-title> <source>Front Med (Lausanne)</source>. <year>2014</year>;<volume>1</volume>:<fpage>24</fpage>. <pub-id pub-id-type="doi">10.3389/fmed.2014.00024</pub-id><pub-id pub-id-type="pmid">25593900</pub-id></mixed-citation></ref>
<ref id="r27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horowitz</surname><given-names>A</given-names></name><name><surname>Chanez-Paredes</surname><given-names>SD</given-names></name><name><surname>Haest</surname><given-names>X</given-names></name><name><surname>Turner</surname><given-names>JR</given-names></name></person-group>. <article-title>Paracellular permeability and tight junction regulation in gut health and disease.</article-title> <source>Nat Rev Gastroenterol Hepatol</source>. <year>2023</year>;<volume>20</volume>(<issue>7</issue>):<fpage>417</fpage>&#x2013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1038/s41575-023-00766-3</pub-id><pub-id pub-id-type="pmid">37186118</pub-id></mixed-citation></ref>
<ref id="r28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Sadi</surname><given-names>R</given-names></name><name><surname>Guo</surname><given-names>S</given-names></name><name><surname>Ye</surname><given-names>D</given-names></name><name><surname>Rawat</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>TY</given-names></name></person-group>. <article-title>TNF-&#x03B1; Modulation of Intestinal Tight Junction Permeability Is Mediated by NIK/IKK-&#x03B1; Axis Activation of the Canonical NF-&#x03BA;B Pathway.</article-title> <source>Am J Pathol</source>. <year>2016</year>;<volume>186</volume>(<issue>5</issue>):<fpage>1151</fpage>&#x2013;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajpath.2015.12.016</pub-id><pub-id pub-id-type="pmid">26948423</pub-id></mixed-citation></ref>
<ref id="r29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nusrat</surname><given-names>A</given-names></name><name><surname>Turner</surname><given-names>JR</given-names></name><name><surname>Madara</surname><given-names>JL</given-names></name></person-group>. <article-title>Molecular physiology and pathophysiology of tight junctions. IV. Regulation of tight junctions by extracellular stimuli: nutrients, cytokines, and immune cells.</article-title> <source>Am J Physiol Gastrointest Liver Physiol</source>. <year>2000</year>;<volume>279</volume>(<issue>5</issue>):<fpage>G851</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1152/ajpgi.2000.279.5.G851</pub-id><pub-id pub-id-type="pmid">11052980</pub-id></mixed-citation></ref>
<ref id="r30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>SV</given-names></name><name><surname>Hopkins</surname><given-names>AM</given-names></name><name><surname>Nusrat</surname><given-names>A</given-names></name></person-group>. <article-title>Modulation of tight junction structure and function by cytokines.</article-title> <source>Adv Drug Deliv Rev</source>. <year>2000</year>;<volume>41</volume>(<issue>3</issue>):<fpage>303</fpage>&#x2013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1016/S0169-409X(00)00048-X</pub-id><pub-id pub-id-type="pmid">10854688</pub-id></mixed-citation></ref>
<ref id="r31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuhan</surname><given-names>R</given-names></name><name><surname>Koutsouris</surname><given-names>A</given-names></name><name><surname>Savkovic</surname><given-names>SD</given-names></name><name><surname>Hecht</surname><given-names>G</given-names></name></person-group>. <article-title>Enteropathogenic Escherichia coli-induced myosin light chain phosphorylation alters intestinal epithelial permeability.</article-title> <source>Gastroenterology</source>. <year>1997</year>;<volume>113</volume>(<issue>6</issue>):<fpage>1873</fpage>&#x2013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/S0016-5085(97)70006-4</pub-id><pub-id pub-id-type="pmid">9394726</pub-id></mixed-citation></ref>
<ref id="r32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sears</surname><given-names>CL</given-names></name></person-group>. <article-title>Molecular physiology and pathophysiology of tight junctions V. assault of the tight junction by enteric pathogens.</article-title> <source>Am J Physiol Gastrointest Liver Physiol</source>. <year>2000</year>;<volume>279</volume>(<issue>6</issue>):<fpage>G1129</fpage>&#x2013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1152/ajpgi.2000.279.6.G1129</pub-id><pub-id pub-id-type="pmid">11093933</pub-id></mixed-citation></ref>
<ref id="r33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furuse</surname><given-names>M</given-names></name><name><surname>Nakatsu</surname><given-names>D</given-names></name><name><surname>Hempstock</surname><given-names>W</given-names></name><name><surname>Sugioka</surname><given-names>S</given-names></name><name><surname>Ishizuka</surname><given-names>N</given-names></name><name><surname>Furuse</surname><given-names>K</given-names></name><etal/></person-group> <article-title>Reconstitution of functional tight junctions with individual claudin subtypes in epithelial cells.</article-title> <source>Cell Struct Funct</source>. <year>2023</year>;<volume>48</volume>(<issue>1</issue>):<fpage>1</fpage>&#x2013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1247/csf.22068</pub-id><pub-id pub-id-type="pmid">36504093</pub-id></mixed-citation></ref>
<ref id="r34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x00FC;nzel</surname><given-names>D</given-names></name><name><surname>Yu</surname><given-names>AS</given-names></name></person-group>. <article-title>Claudins and the modulation of tight junction permeability.</article-title> <source>Physiol Rev</source>. <year>2013</year>;<volume>93</volume>(<issue>2</issue>):<fpage>525</fpage>&#x2013;<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.00019.2012</pub-id><pub-id pub-id-type="pmid">23589827</pub-id></mixed-citation></ref>
<ref id="r35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Hernandez</surname><given-names>V</given-names></name><name><surname>Quiros</surname><given-names>M</given-names></name><name><surname>Nusrat</surname><given-names>A</given-names></name></person-group>. <article-title>Intestinal epithelial claudins: expression and regulation in homeostasis and inflammation.</article-title> <source>Ann N Y Acad Sci</source>. <year>2017</year>;<volume>1397</volume>(<issue>1</issue>):<fpage>66</fpage>&#x2013;<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1111/nyas.13360</pub-id><pub-id pub-id-type="pmid">28493289</pub-id></mixed-citation></ref>
<ref id="r36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lameris</surname><given-names>AL</given-names></name><name><surname>Huybers</surname><given-names>S</given-names></name><name><surname>Kaukinen</surname><given-names>K</given-names></name><name><surname>M&#x00E4;kel&#x00E4;</surname><given-names>TH</given-names></name><name><surname>Bindels</surname><given-names>RJ</given-names></name><name><surname>Hoenderop</surname><given-names>JG</given-names></name><etal/></person-group> <article-title>Expression profiling of claudins in the human gastrointestinal tract in health and during inflammatory bowel disease.</article-title> <source>Scand J Gastroenterol</source>. <year>2013</year>;<volume>48</volume>(<issue>1</issue>):<fpage>58</fpage>&#x2013;<lpage>69</lpage>. <pub-id pub-id-type="doi">10.3109/00365521.2012.741616</pub-id><pub-id pub-id-type="pmid">23205909</pub-id></mixed-citation></ref>
<ref id="r37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holmes</surname><given-names>JL</given-names></name><name><surname>Van Itallie</surname><given-names>CM</given-names></name><name><surname>Rasmussen</surname><given-names>JE</given-names></name><name><surname>Anderson</surname><given-names>JM</given-names></name></person-group>. <article-title>Claudin profiling in the mouse during postnatal intestinal development and along the gastrointestinal tract reveals complex expression patterns.</article-title> <source>Gene Expr Patterns</source>. <year>2006</year>;<volume>6</volume>(<issue>6</issue>):<fpage>581</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.modgep.2005.12.001</pub-id><pub-id pub-id-type="pmid">16458081</pub-id></mixed-citation></ref>
<ref id="r38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujita</surname><given-names>H</given-names></name><name><surname>Chiba</surname><given-names>H</given-names></name><name><surname>Yokozaki</surname><given-names>H</given-names></name><name><surname>Sakai</surname><given-names>N</given-names></name><name><surname>Sugimoto</surname><given-names>K</given-names></name><name><surname>Wada</surname><given-names>T</given-names></name><etal/></person-group> <article-title>Differential expression and subcellular localization of claudin-7, -8, -12, -13, and -15 along the mouse intestine.</article-title> <source>J Histochem Cytochem</source>. <year>2006</year>;<volume>54</volume>(<issue>8</issue>):<fpage>933</fpage>&#x2013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1369/jhc.6A6944.2006</pub-id><pub-id pub-id-type="pmid">16651389</pub-id></mixed-citation></ref>
<ref id="r39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahner</surname><given-names>C</given-names></name><name><surname>Mitic</surname><given-names>LL</given-names></name><name><surname>Anderson</surname><given-names>JM</given-names></name></person-group>. <article-title>Heterogeneity in expression and subcellular localization of claudins 2, 3, 4, and 5 in the rat liver, pancreas, and gut.</article-title> <source>Gastroenterology</source>. <year>2001</year>;<volume>120</volume>(<issue>2</issue>):<fpage>411</fpage>&#x2013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1053/gast.2001.21736</pub-id><pub-id pub-id-type="pmid">11159882</pub-id></mixed-citation></ref>
<ref id="r40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>L</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Foreman</surname><given-names>O</given-names></name><name><surname>Tatum</surname><given-names>R</given-names></name><name><surname>Lu</surname><given-names>Q</given-names></name><name><surname>Renegar</surname><given-names>R</given-names></name><etal/></person-group> <article-title>Inflammation and disruption of the mucosal architecture in claudin-7-deficient mice.</article-title> <source>Gastroenterology</source>. <year>2012</year>;<volume>142</volume>(<issue>2</issue>):<fpage>305</fpage>&#x2013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1053/j.gastro.2011.10.025</pub-id><pub-id pub-id-type="pmid">22044670</pub-id></mixed-citation></ref>
<ref id="r41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hering</surname><given-names>NA</given-names></name><name><surname>Fromm</surname><given-names>M</given-names></name><name><surname>Schulzke</surname><given-names>JD</given-names></name></person-group>. <article-title>Determinants of colonic barrier function in inflammatory bowel disease and potential therapeutics.</article-title> <source>J Physiol</source>. <year>2012</year>;<volume>590</volume>(<issue>5</issue>):<fpage>1035</fpage>&#x2013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1113/jphysiol.2011.224568</pub-id><pub-id pub-id-type="pmid">22219336</pub-id></mixed-citation></ref>
<ref id="r42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>R</given-names></name><name><surname>Kumar</surname><given-names>B</given-names></name><name><surname>Thapa</surname><given-names>I</given-names></name><name><surname>Tamang</surname><given-names>RL</given-names></name><name><surname>Yadav</surname><given-names>SK</given-names></name><name><surname>Washington</surname><given-names>MK</given-names></name><etal/></person-group> <article-title>Claudin-2 protects against colitis-associated cancer by promoting colitis-associated mucosal healing.</article-title> <source>J Clin Invest</source>. <year>2023</year>;<volume>133</volume>(<issue>23</issue>): <pub-id pub-id-type="doi">10.1172/JCI170771</pub-id><pub-id pub-id-type="pmid">37815870</pub-id></mixed-citation></ref>
<ref id="r43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x010C;u&#x017E;i&#x0107;</surname><given-names>S</given-names></name><name><surname>Antoli&#x0107;</surname><given-names>M</given-names></name><name><surname>Ognjenovi&#x0107;</surname><given-names>A</given-names></name><name><surname>Stupin-Polan&#x010D;ec</surname><given-names>D</given-names></name><name><surname>Petrini&#x0107; Grba</surname><given-names>A</given-names></name><name><surname>Hrva&#x010D;i&#x0107;</surname><given-names>B</given-names></name><etal/></person-group> <article-title>Claudins: Beyond Tight Junctions in Human IBD and Murine Models.</article-title> <source>Front Pharmacol</source>. <year>2021</year>;<volume>12</volume>:<elocation-id>682614</elocation-id>. <pub-id pub-id-type="doi">10.3389/fphar.2021.682614</pub-id><pub-id pub-id-type="pmid">34867313</pub-id></mixed-citation></ref>
<ref id="r44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zammarchi</surname><given-names>I</given-names></name><name><surname>Santacroce</surname><given-names>G</given-names></name><name><surname>Puga-Tejada</surname><given-names>M</given-names></name><name><surname>Hayes</surname><given-names>B</given-names></name><name><surname>Crotty</surname><given-names>R</given-names></name><name><surname>O&#x2019;Driscoll</surname><given-names>E</given-names></name><etal/></person-group> <article-title>Epithelial neutrophil localization and tight junction Claudin-2 expression are innovative outcome predictors in inflammatory bowel disease.</article-title> <source>United European Gastroenterol J</source>. <year>2024</year>;<volume>12</volume>(<issue>9</issue>):<fpage>1155</fpage>&#x2013;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1002/ueg2.12677</pub-id><pub-id pub-id-type="pmid">39361538</pub-id></mixed-citation></ref>
</ref-list>
</back>
</article>
